Back to top
more

Twist Bioscience Corporation (TWST)

(Real Time Quote from BATS)

$185.87 USD

185.87
355,536

-4.77 (-2.50%)

Updated Jan 25, 2021 01:55 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 13% (221 out of 253)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for TWST

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Twist Bioscience Corporation falls in the month of September.

All items in Millions except Per Share data.

9/30/2020 9/30/2019 9/30/2018 9/30/2017 9/30/2016
Assets          
Cash & Equivalents 290 138 81 62 0
Receivables 26 12 5 2 0
Notes Receivable 0 0 0 0 0
Inventories 12 7 6 2 0
Other Current Assets 6 3 3 1 0
Total Current Assets 335 160 96 68 0
Net Property & Equipment 25 21 12 15 0
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 1 2 2 2 0
Deposits & Other Assets 3 4 6 1 0
Total Assets 399 187 116 86 0
Liabilities & Shareholders Equity 9/30/2020 9/30/2019 9/30/2018 9/30/2017 9/30/2016
Notes Payable 0 0 0 0 0
Accounts Payable 5 10 8 3 0
Current Portion Long-Term Debt 3 3 3 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 19 16 8 6 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 3 1 1 1 0
Total Current Liabilities 36 30 19 9 0
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 1 4 7 9 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 1 1 0
Total Liabilities 63 35 27 19 0
Shareholders Equity 9/30/2020 9/30/2019 9/30/2018 9/30/2017 9/30/2016
Preferred Stock 0 0 290 200 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 795 470 9 6 0
Retained Earnings -458 -319 -211 -140 0
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 336 152 89 66 0
Total Liabilities & Shareholder's Equity 399 187 116 86 0
Total Common Equity 336 152 -201 -133 0
Shares Outstanding 44.60 32.80 NA NA NA
Book Value Per Share 7.54 4.64 0.00 0.00 0.00

Fiscal Year End for Twist Bioscience Corporation falls in the month of September.

All items in Millions except Per Share data.

12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Assets          
Cash & Equivalents NA 290 312 230 103
Receivables NA 26 13 15 13
Notes Receivable NA 0 0 0 0
Inventories NA 12 13 11 7
Other Current Assets NA 6 6 5 6
Total Current Assets NA 335 345 260 129
Net Property & Equipment NA 25 24 23 21
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 1 1 2 2
Deposits & Other Assets NA 3 3 3 3
Total Assets NA 399 408 324 192
Liabilities & Shareholders Equity 12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Notes Payable NA 0 0 0 0
Accounts Payable NA 5 6 7 9
Current Portion Long-Term Debt NA 3 3 3 3
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 19 14 12 36
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 3 1 0 1
Total Current Liabilities NA 36 31 30 58
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 1 2 3 4
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 63 59 60 89
Shareholders Equity 12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 795 783 670 477
Retained Earnings NA -458 -434 -406 -374
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 336 349 264 103
Total Liabilities & Shareholder's Equity NA 399 408 324 192
Total Common Equity 0 336 349 264 103
Shares Outstanding 45.10 44.60 40.90 35.40 33.20
Book Value Per Share 0.00 7.54 8.53 7.46 3.10